Quantifying beta cell function in the preclinical stages of type 1 diabetes

Area of Science:

• Endocrinology and Metabolism
• Immunology
• Diabetes Research

Background:

• Type 1 diabetes (T1D) progresses through pre-symptomatic stages (Stage 1 and 2) before clinical symptoms arise.
• This progression involves the autoimmune destruction of pancreatic beta cells, leading to impaired insulin production.
• Early detection and monitoring of beta cell function are vital for managing T1D and testing interventions.

Purpose of the Study:

• To review metabolic changes in early pre-symptomatic type 1 diabetes.
• To identify reliable metabolic tests for tracking beta cell function longitudinally.
• To discuss the application of metabolic modeling and novel monitoring techniques.

Main Methods:

• Review of existing literature on metabolic alterations in pre-symptomatic T1D.
• Analysis of dynamic tests like the Oral Glucose Tolerance Test (OGTT).
• Evaluation of metabolic modeling, risk indices, and continuous glucose monitoring (CGM) data.

Main Results:

• Pre-symptomatic T1D is characterized by declining beta cell mass and function, with varying glucose tolerance.
• Metabolic modeling can quantify insulin secretion and sensitivity changes.
• OGTT, risk indices, and CGM offer measurable outcomes for disease tracking.

Conclusions:

• Accurate assessment of beta cell function is essential for monitoring T1D development.
• A combination of dynamic testing, metabolic modeling, and CGM holds promise for early detection and intervention.
• Longitudinal tracking of metabolic changes aids in understanding disease trajectory and therapeutic efficacy.